• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

DirectSense RF Sub-study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number P150005 S049/ PAS001
Date Current Protocol Accepted  
Study Name DirectSense RF Sub-study
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The purpose of the DirectSense RF sub-study is to collect data to support the use and labeling for the new DIRECTSENSE™ RF feature used with IntellaNav MiFi Open Irrigated Ablation Catheters to treat Paroxysmal Atrial Fibrillation.
Study Population Description The sub-study will enroll patients from the INTERRUPT AF PAS who are treated using the DirectSense RF feature during the cardiac ablation procedure.
Sample Size 156 subjects treated with DirectSense RF from INTERRUPT AF PAS will be included in the DirectSense RF sub-study.
Data Collection Safety: The primary safety endpoint is defined as the safety event-free rate at 12 months post-procedure.

Effectiveness: The primary effectiveness endpoint is defined as the event-free rate at 12 months post-procedure

Follow-up Visits and Length of Follow-up 3 years


DirectSense RF Sub-study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 10/16/2020 10/23/2020 Overdue/Received
18 month report 11/01/2021    
30 month report 11/01/2022    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-